MedTrace Logo

Peripheral Blood Stem Cell Transplantation Using the CliniMACS Device

NCT01071226 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-10-25

No results posted yet for this study

Summary

T cell depletion utilizing the CliniMACS device will allow more precise, specific and controlled graft engineering of peripheral blood stem cells from unrelated and partially matched related donors without an increase in relapse or graft rejection and grade III or IV acute graft versus host disease (GVHD).

Conditions

  • Malignant Diseases (ie, Leukemia, MDS, Lymphoma)
  • Non-malignant Diseases (ie, Bone Marrow Failure Syndromes)

Interventions

DEVICE

CliniMACS (CD+3, CD+19 depletion)

Patient's in Stratum 1 will receive grafts that have undergone CD3+, CD19+ depletion

DEVICE

CliniMACS (CD 34+ positive selection)

Patient's in Stratum 2 will receive peripheral blood progenitor cells that have undergone CD34+ selection

OTHER

HSCT

Peripheral Blood Stem Cell Transplant

Sponsors & Collaborators

Principal Investigators

  • Julie A Talano, MD · Medical College of Wisconsin

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2016-08-31
Completion
2020-04-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01071226 on ClinicalTrials.gov